Silexion Therapeutics Corp. has released a corporate presentation detailing its progress in developing RNA silencing treatments targeting mutated KRAS proteins, which are key drivers in several aggressive cancers, including pancreatic, colorectal, lung, small bowel, and appendix cancers. The company's first-generation product, Loder, demonstrated a survival benefit in clinical studies for patients with mutant KRAS-driven locally advanced pancreatic cancer. In these studies, patients receiving Loder in combination with standard-of-care chemotherapy showed a median overall survival of 22.7 months compared to 13.4 months for those on chemotherapy alone. Silexion's second-generation siRNA candidate, SIL204, is designed to enhance cellular delivery, improve stability, and offer broader antitumor activity. The platform supports both intratumor and systemic administration, aiming to treat both primary tumors and metastases. Preclinical results with SIL204 indicate potential applicability for mutant KRAS-positive pancreatic, colorectal, and lung cancers. You can access the full presentation through the link below.